San Francisco startup Framework Therapeutics can be working on an oral, when-day-to-day GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June when a mid-phase review confirmed ordinary weight loss of around six% and it programs to start A further